- Home
- AIRT vs PSTV Comparison
AIRT vs PSTV Comparison
Compare AIRT & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRT | PSTV |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2M | 61.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AIRT | PSTV |
|---|---|---|
| Price | $18.75 | $0.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.25 |
| AVG Volume (30 Days) | 2.1K | ★ 4.6M |
| Earning Date | 02-11-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $279,216,000.00 | $5,258,000.00 |
| Revenue This Year | N/A | $1.73 |
| Revenue Next Year | N/A | $12.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.56 | $0.16 |
| 52 Week High | $26.70 | $2.31 |
Technical Indicators
Market Signals| Indicator | AIRT | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 43.11 |
| Support Level | $19.00 | $0.54 |
| Resistance Level | $20.75 | $0.58 |
| Average True Range (ATR) | 0.45 | 0.05 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 12.90 | 4.00 |
Price Performance
Historical ComparisonAbout AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).